Skip to main content
. 2024 Jan 5;24:23. doi: 10.1186/s12877-023-04601-x

Table 2.

Number and percentage of participants having each health condition at baseline, 12-month, and 24-month follow-ups

Baseline
(N = 1472)
12-month follow-up
(N = 1130)
24-month follow-up
(N = 806)
Health conditions
Yes, N (%)
Myocardial infarction (history of heart attacks) 130 (8.8) 128 (11.3) 96 (11.9)
Congestive heart failure 67 (4.6) 68 (6.0) 53 (6.6)
Hypertension/high blood pressure 566 (38.5) 509 (45.0) 390 (48.4)
Diagnosed depression 221 (15.0) 212 (18.8) 187 (23.2)
Peripheral vascular disease 152 (10.3) 183 (16.2) 157 (19.5)
Aortic aneurysm 19 (1.3) 20 (1.77) 18 (2.2)
Poor circulation 93 (6.3) 116 (20.3) 107 (13.3)
Cerebrovascular disease 228 (15.5) 216 (19.1) 166 (20.6)
Stroke 110 (7.5) 105 (9.3) 79 (9.8)
Cerebrovascular accident 7 (0.5) 7 (0.6) 4 (0.5)
Transient Ischemic attack 108 (7.3) 124 (11.0) 104 (12.9)
Chronic bad chest 200 (13.6) 181 (16.0) 134 (16.6)
Asthma 103 (7.0) 99 (8.8) 74 (9.2)
Chronic obstructive pulmonary disease 53 (3.6) 54 (4.8) 38 (4.7)
Chronic bronchitis 19 (1.3) 20 (1.8) 19 (2.4)
Emphysema 14 (1.0) 19 (1.7) 16 (2.0)
Inflammation affecting the joints 434 (29.5) 416 (36.8) 340 (42.2)
Lupus 2 (0.1) 2 (0.2) 0 (0)
Rheumatoid arthritis 205 (13.9) 233 (20.6) 212 (26.3)
Connective tissue disease 10 (0.7) 10 (0.9) 5 (0.6)
Vasculitis 8 (0.5) 11 (1.0) 8 (1.0)
Peptic/stomach ulcer disease 59 (4.01) 54 (0.4) 42 (5.2)
Skin ulcer 24 (1.6) 35 (3.1) 31 (3.8)
Bed sores 4 (0.3) 6 (0.5) 3 (0.4)
Repeated cellulitis 8 (0.5) 13 (1.2) 13 (1.6)
Diabetes controlled with insulin or equivalent 189 (12.8) 171 (15.1) 132 (16.4)
Diabetes with end organ damage 29 (2.0) 23 (2.0) 29 (3.6)
Damage to the retina 12 (0.8) 13 (1.2) 11 (1.4)
Nerve damage 6 (0.4) 10 (0.9) 12 (1.5)
Kidney damage 9 (0.6) 7 (0.6) 9 (1.1)
Brittle diabetes 2 (0.1) 2 (0.2) 2 (0.2)
Moderate or severe chronic kidney disease 38 (2.6) 39 (3.5) 34 (3.0)
Hemiplegia 3 (0.2) 5 (0.4) 4 (0.5)
Cancer within the last five years 134 (9.1) 134 (11.9) 115 (14.3)
Breast cancer 28 (1.9) 24 (2.1) 18 (2.2)
Colon cancer 11 (0.7) 16 (1.4) 15 (1.9)
Prostate cancer 45 (3.1) 44 (3.9) 29 (3.6)
Lung cancer 4 (0.3) 3 (0.3) 4 (0.5)
Skin cancer 19 (1.3) 20 (1.8) 23 (2.9)
Blood cancer/lymphoma 4 (0.3) 5 (0.4) 6 (0.7)
Acute or chronic leukemia 0 (0) 1 (0.1) 2 (0.2)
Cancer within the past five years that has metastasized 7 (0.5) 12 (1.1) 12 (1.5)
Mild liver disease 5 (0.3) 7 (0.6) 5 (0.6)
Hepatitis B 0 (0) 5 (0.4) 0 (0)
Hepatitis C 0 (0) 0 (0) 0 (0)
Cirrhosis 2 (0.1) 2 (0.2) 1 (0.1)
Liver disease (moderate to severe) 1 (0.1) 3 (0.3) 0 (0)
Chronic jaundice 1 (0.1) 1 (0.1) 0 (0)
Liver failure 1 (0.1) 2 (0.2) 0 (0)
Liver transplant 0 (0) 0 (0) 0 (0)
AIDS or HIV 0 (0) 0 (0) 0 (0)
Taking warfarin 154 (10.5) 115 (10.2) 74 (9.2)

In the present study we were interested in the count of health conditions. However, conditions that are typically weighted as having a higher impact on health and the cost of care are hemiplegia, moderate or severe chronic kidney disease, diabetes with end of organ damage, any cancer, skin ulcers/cellulitis, moderate or severe live disease, metastatic cancer, and AIDS or HIV. In the weighted CCI total score all these conditions receive a weight of two except for moderate or severe liver disease which receives a weight of three and metastatic cancer and AIDS or HIV which receive a weight of six. The remaining conditions, and taking warfarin, receive a weight of one [35]